Corrigendum: LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma
- 1State Key Laboratory of Oncology in South China, Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
- 2Department of Radiotherapy, Eye & ENT Hospital, Fudan University, Shanghai, China
- 3Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
- 4NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma (Jiangxi Cancer Hospital of Nanchang University), Nanchang, China
by Zhang, M.-X., Wang, L., Zeng, L., and Tu, Z.-W. (2021). Front. Oncol. 10:605777. doi: 10.3389/fonc.2020.605777
An author name was incorrectly spelled as Lei Zheng. The correct spelling is Lei Zeng.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: nasopharyngeal carcinoma, lipocalin 2, hypoxia-inducible factor 1-alpha, radioresistance, recurrence
Citation: Zhang M-X, Wang L, Zeng L and Tu Z-W (2021) Corrigendum: LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma. Front. Oncol. 11:670714. doi: 10.3389/fonc.2021.670714
Received: 22 February 2021; Accepted: 22 February 2021;
Published: 18 March 2021.
Approved by:Frontiers Editorial Office, Frontiers Media SA, Switzerland
Copyright © 2021 Zhang, Wang, Zeng and Tu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
†These authors have contributed equally to this work